Global Gene Therapy for CNS Disorders Market 2019-2023
About this market
The increase in special drug designations is one of the key factors anticipated to witness continuous growth in the forthcoming years. Vendors are receiving special drug designations for their novel gene therapies to help in receiving quicker approval. Some market players are even offering the orphan drug designation with various tax benefits on their clinical researches. As a result, the rising number of special drug designations from the regulatory bodies will drive the gene therapy for CNS disorders market growth in the forthcoming years. Technavio’s analysts have predicted that the gene therapy for CNS disorders market will register a CAGR of nearly 27% by 2023.
Increase in special drug designations
One of the growth drivers of the global gene therapy for CNS disorders market is the increase in special drug designations. The increasing number of special drug designations from the regulatory bodies is expected to result in the quicker approval of gene therapy programs, which drives the growth of the market.
Uneven distribution of technology
One of the challenges in the growth of the global gene therapy for CNS disorders market is the Uneven distribution of technology. The lack of focus of major vendors on developing gene therapy for CNS disorders are expected to hinder the market growth during the forecast period.
For the detailed list of factors that will drive and challenge the growth of the gene therapy for CNS disorders market during 019-2023, view our report.
The market appears to be highly concentrated with the presence of a few market players. Vendors in the market are developing advanced technologies that help in manufacturing gene therapies with superior efficacy for the treatment of various CNS indications. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.
Technavio Announces the Publication of its Research Report – Global Gene Therapy for CNS Disorders Market 2019-2023
Technavio recognizes the following companies as the key players in the global gene therapy for CNS disorders market: Biogen, bluebird bio, Inc., Novartis AG, Pfizer Inc., and Voyager Therapeutics.
Commenting on the report, an analyst from Technavio’s team said: “The latest trend gaining momentum in the market is the changing perception related to ethical issues.”
According to the report, one of the major drivers for this market is the advent of novel technologies.
Further, the report states that one of the major factors hindering the growth of this market is the uneven distribution of technology.
bluebird bio, Inc.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook